Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.600
+0.010 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
July 12, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
July 11, 2023
Via
Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
June 21, 2023
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy.
Via
InvestorPlace
Analyst Expectations for Revance Therapeutics's Future
June 07, 2023
Via
Benzinga
Earnings Preview For Revance Therapeutics
May 08, 2023
Via
Benzinga
7 Analysts Have This to Say About Revance Therapeutics
April 11, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Revance Therapeutics
January 24, 2023
Via
Benzinga
Revance to Participate in Upcoming Investor Conferences
May 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
May 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
May 02, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
April 05, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
7 Stocks to Buy for the Massive Rally Ahead
April 04, 2023
With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally.
Via
InvestorPlace
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 30, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
March 07, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
March 02, 2023
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.
Via
MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
February 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 21, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
3 Pharma Stocks That Will Mint Millionaires
January 30, 2023
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters.
Via
InvestorPlace
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
January 19, 2023
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 11, 2023
Via
Benzinga
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today
January 09, 2023
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500...
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 09, 2023
Via
Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
January 09, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.